Alpha Teknova, Inc.
HealthcareNASDAQ:TKNO · NASDAQ Global Market
-$0.20 today
Vol 0.15M · Avg 0.13M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$17.3M +35.5% | -$26.7M +27.3% | -$36.8M +22.5% | -$47.5M -384.2% | -$9.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $6.3M -3.6% | $6.6M +16.2% | $5.7M +78.8% | $3.2M +9.8% | $2.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $52.0K +156.5% | -$92.0K +69.7% | -$304.0K +84.2% | -$1.9M +32.0% | -$2.8M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $3.4M -6.5% | $3.7M -11.4% | $4.1M +11.5% | $3.7M +139.3% | $1.6M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$2.7M -206.9% | -$873.0K -138.8% | $2.2M +130.7% | -$7.3M -314.6% | -$1.8M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$374.0K +24.3% | -$494.0K -257.3% | $314.0K -17.4% | $380.0K +875.5% | -$49.0K | $592.6M | $1.3B | $626.2M |
| Inventory | -$2.4M -1070.5% | $244.0K -26.1% | $330.0K +104.4% | -$7.5M -235.1% | -$2.3M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $470.0K +179.1% | -$594.0K +23.2% | -$773.0K -235.1% | $572.0K +111.9% | $270.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$407.0K -1303.4% | -$29.0K -101.2% | $2.4M +423.1% | -$736.0K -379.8% | $263.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $1.5M -71.1% | $5.1M -18.5% | $6.2M -72.3% | $22.5M +2378.6% | $906.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$8.6M +30.2% | -$12.4M +34.1% | -$18.8M +31.3% | -$27.4M -202.1% | -$9.1M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.1M -2.0% | -$1.1M +85.8% | -$7.9M +71.8% | -$28.1M -41.6% | -$19.9M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$17.2M +43.3% | -$30.3M | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $29.0M +625.0% | $4.0M | $0 | $0 -100.0% | $1.8M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 -100.0% | $125.0K -36.5% | $197.0K | $0 -100.0% | $529.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $10.7M +139.2% | -$27.3M -252.5% | -$7.7M +72.5% | -$28.1M -60.7% | -$17.5M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $1.1M | $0 +100.0% | -$10.0M -198.7% | $10.1M -14.8% | $11.9M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $211.0K -98.6% | $15.1M -32.9% | $22.5M +5026.0% | $439.0K -99.6% | $102.7M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$1.2M -446.7% | -$214.0K -568.8% | -$32.0K +89.6% | -$307.0K +91.9% | -$3.8M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $151.0K -99.0% | $14.9M +16.3% | $12.8M +24.7% | $10.3M -90.7% | $110.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $2.2M +108.9% | -$24.8M -80.2% | -$13.8M +69.6% | -$45.3M -153.8% | $84.2M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$9.8M +27.5% | -$13.5M +49.5% | -$26.7M +51.8% | -$55.5M -91.9% | -$28.9M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$679.20M
Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
$600.84M
Canopy Growth Corporation
NASDAQ:CGC
$425.84M
NeoGenomics, Inc.
NASDAQ:NEO
$290.37M
Lifecore Biomedical, Inc.
NASDAQ:LFCR
$211.55M
Aurora Cannabis Inc.
NASDAQ:ACB
$172.40M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$151.72M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
Exagen Inc.
NASDAQ:XGN
$112.83M
Immutep Limited
NASDAQ:IMMP
$53.60M
SEC Filings
Recent regulatory filings
No filings found.
Does TKNO generate free cash flow?
Alpha Teknova, Inc. (TKNO) generated -$9,794,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does TKNO produce?
Operating cash flow was -$8,646,000.00, before capital expenditures of $1.15M.
Explore More
Continue the stock analysis
Jump to another research area for this company.